(Q41478162)

1 October 2017

1 reference

title

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences (English)

1 reference

(3S)-3-hydroxy-3-methylglutaryl-CoA

1 October 2017

1 reference

3-hydroxy-3-methylglutaryl-CoA

ChEBI release 2020-05-28

ChEBI ID

15467

1 reference

ChEBI release 2020-05-28

1 reference

Lennernäs H

1

1 reference

PubMed ID

9160173

1 October 2017

Fager G

series ordinal

2

1 reference

1 October 2017

1 May 1997

1 reference

Clinical Pharmacokinetics

1 October 2017

1 reference

1 October 2017

32

1 reference

1 October 2017

403-425

1 reference

1 October 2017

5

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199732050-00005

1 October 2017

0 references

cites work

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

1 reference

12 December 2020

Steady state serum concentrations of pravastatin and digoxin when given in combination

1 reference

12 December 2020

Regulation of the mevalonate pathway

1 reference

12 December 2020

Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management

1 reference

12 December 2020

Lovastatin. Warfarin interaction

1 reference

12 December 2020

Interaction between fibre and lovastatin

1 reference

12 December 2020

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.

1 reference

12 December 2020

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

1 reference

12 December 2020

Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin

1 reference

12 December 2020

In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

1 reference

12 December 2020

Lack of interaction between ramipril and simvastatin

1 reference

12 December 2020

Pharmacokinetics of pravastatin in elderly versus young men and women

1 reference

12 December 2020

Cholesterol reduction and its impact on coronary artery disease and total mortality

1 reference

12 December 2020

Chronokinetics of Pravastatin Administered in the PM Compared with AM Dosing.

1 reference

12 December 2020

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

1 reference

12 December 2020

Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans

1 reference

12 December 2020

Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo

1 reference

12 December 2020

Effect of food on pravastatin pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin

1 reference

12 December 2020

Clinical pharmacokinetics and practical applications of simvastatin

1 reference

12 December 2020

Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Binding of fluvastatin to blood cells and plasma proteins

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin.

1 reference

12 December 2020

A receptor-mediated pathway for cholesterol homeostasis

1 reference

12 December 2020

Lovastatin: a new cholesterol-lowering agent

1 reference

12 December 2020

HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies

1 reference

12 December 2020

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

1 reference

12 December 2020

Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier

1 reference

12 December 2020

Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia

1 reference

12 December 2020

An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence

1 reference

12 December 2020

Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A

1 reference

12 December 2020

Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects

1 reference

12 December 2020

Biotransformation of fluvastatin sodium in humans

1 reference

12 December 2020

Hepatoselective carrier-mediated sodium-independent uptake of pravastatin and pravastatin-lactone

1 reference

12 December 2020

Physiological disposition of HMG-CoA-reductase inhibitors

1 reference

12 December 2020

Regioselectivity and stereoselectivity in the metabolism of HMG-CoA reductase inhibitors

1 reference

12 December 2020

The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.

1 reference

12 December 2020

Updated clinical safety experience with fluvastatin

1 reference

12 December 2020

Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers

1 reference

12 December 2020

Efficacy and pharmacokinetics of simvastatin in heart transplant recipients

1 reference

12 December 2020

The interaction of lovastatin and warfarin

1 reference

12 December 2020

Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers

1 reference

12 December 2020

Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.

1 reference

12 December 2020

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

1 reference

12 December 2020

Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. 4

1 reference

12 December 2020

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

1 reference

12 December 2020

Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin

1 reference

12 December 2020

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

1 reference

12 December 2020

Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat

1 reference

12 December 2020

Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting.

1 reference

12 December 2020

The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects

1 reference

12 December 2020

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

1 reference

12 December 2020

Jejunal permeability and hepatic extraction of fluvastatin in humans

1 reference

12 December 2020

Pharmacokinetics of fluvastatin and specific drug interactions

1 reference

12 December 2020

Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit

1 reference

12 December 2020

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

1 reference

12 December 2020

Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues

1 reference

12 December 2020

The physiological disposition of lovastatin

1 reference

12 December 2020

Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat.

1 reference

12 December 2020

Correlation of drug absorption with molecular surface properties

1 reference

12 December 2020

High lipophilicity decreases drug transport across intestinal epithelial cells

1 reference

12 December 2020

Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods.

1 reference

12 December 2020

Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug

1 reference

12 December 2020

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

1 reference

12 December 2020

Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase

1 reference

12 December 2020

Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

12 December 2020

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.

1 reference

12 December 2020

Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey

1 reference

12 December 2020

Biotransformation of pravastatin sodium in humans

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin

1 reference

12 December 2020

A review of clinical trials comparing HMG-CoA reductase inhibitors

1 reference

12 December 2020

Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae

1 reference

12 December 2020

Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium

1 reference

12 December 2020

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients

1 reference

12 December 2020

Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers

1 reference

12 December 2020

Multiple transport systems for organic anions across the bile canalicular membrane

1 reference

12 December 2020

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

1 reference

12 December 2020

Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture

1 reference

12 December 2020

Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin

1 reference

12 December 2020

Clinical pharmacokinetics of pravastatin

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase

1 reference

12 December 2020

A Randomized Multicenter Trial Comparing and Efficacy of Simvastatin and Fluvastatin

1 reference

12 December 2020

Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue

1 reference

12 December 2020

Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats.

1 reference

12 December 2020

Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

The biology of the P-glycoproteins

1 reference

12 December 2020

Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man

1 reference

12 December 2020

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

1 reference

12 December 2020

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

12 December 2020

Gastrointestinal absorption of pravastatin in healthy subjects

1 reference

12 December 2020

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin

1 reference

12 December 2020

HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells

1 reference

12 December 2020

10.2165/00003088-199732050-00005

Identifiers

DOI

1 reference

PubMed ID

9160173

Dimensions Publication ID

1 October 2017

0 references

1 reference

PubMed ID

9160173